Roche Annual General Meeting 2025
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) held its Annual General Meeting where shareholders approved all Board of Directors' proposals with 77.03% of total shares represented. Dr Severin Schwan was re-elected as Chairman with 97.93% approval.
Key highlights include:
- Approval of the 38th consecutive dividend increase to CHF 9.70 per share
- Confirmation of 2024 Annual Financial Statements, Consolidated Financial Statements, Remuneration Report, and Sustainability Report
- Re-election of all Board members for one-year terms
- Appointment of KPMG AG as statutory auditors for 2025
Shareholders also approved the Corporate Executive Committee's total bonuses for 2024 (95.00% approval) and maximum future remuneration for both Board of Directors (95.15%) and Corporate Executive Committee (95.22%) until the 2026 Annual General Meeting.
Positive
- 38th consecutive annual dividend increase, showing strong financial stability
- High shareholder approval rates (>95%) for executive compensation and board elections
- Strong shareholder representation at 77.03% of total shares
Negative
- None.
News Market Reaction
On the day this news was published, RHHBY gained 1.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Shareholders approved all proposals of the Board of Directors
- Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed
- 38th consecutive dividend increase to CHF 9.70 per share
Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders in attendance, who represented
Dr Severin Schwan was re-elected as Chairman of the Board of Directors by
“2024 was a good year for our company. Demand for our innovative diagnostic tests and medicines increased significantly. Most importantly, we also introduced many innovations to patients, continuing to help prevent, stop and cure diseases. I have great confidence that Roche will continue to be successful in the years to come with our in-depth expertise in Pharmaceuticals and Diagnostics, our end-to-end approaches, the use of cutting-edge technology and a promising pipeline.”
In addition, the shareholders approved an increase in the dividend for the past financial year to 9.70 Swiss francs (gross) per share and non-voting equity security. This is the 38th consecutive dividend increase. The shareholders also authorised the discharge of the members of the Board of Directors and the Corporate Executive Committee.
The shareholders approved the total bonuses of the Corporate Executive Committee for the 2024 financial year by
In addition to Severin Schwan, all other members of the Board of Directors who were up for election were re-elected to the Board of Directors for a one-year term:
- Mr André Hoffmann
- Dr Jörg Duschmalé
- Dr Patrick Frost
- Ms Anita Hauser
- Professor Dr Akiko Iwasaki
- Professor Dr Richard P. Lifton
- Dr Jemilah Mahmood
- Dr Mark Schneider
- Dr Claudia Suessmuth Dyckerhoff
The following Board members standing for election were re-elected to the Remuneration Committee for a one-year term:
- Dr Jörg Duschmalé
- Ms Anita Hauser
- Professor Dr Richard P. Lifton
The Annual General Meeting appointed KPMG AG as statutory auditors for the 2025 financial year and Testaris AG as independent proxy until the conclusion of the 2026 Annual General Meeting.
The address by Chairman of the Board of Directors Severin Schwan to shareholders will be available at https://www.roche.com/about/governance/annual-general-meetings.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
| Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
What is the new dividend amount for Roche (RHHBY) shareholders in 2025?
How many consecutive years has Roche (RHHBY) increased its dividend?
What was the shareholder approval rate for Roche's (RHHBY) Chairman re-election in 2025?
What percentage of Roche (RHHBY) shares were represented at the 2025 Annual General Meeting?
What was the approval rate for Roche's (RHHBY) executive compensation package for 2024?
